10 No-Brainer Stocks to Buy Now
Fed Chair Kevin Warsh gave no hint of another rate hike at an IMF event in Bangkok on October 16, and the odds of an October increase fell to roughly 15% on CME FedWatch, according to Benzinga on October...
Novartis A G (NVS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 15,119 | $2,155,515 | +10% | 0.04% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 185,430 | $26,436,755 | 0.32% | |
| 2. | 181,232 | $25,838,247 | 2.13% | |
| 3. | 132,255 | $18,855,599 | 0.25% | |
| 4. | 135,549 | $17,584,611 | 0.03% | |
| 5. | 103,905 | $14,661,224 | 0.04% |
News See All
SpaceX Stock Forecast: ClearBridge Fund Exits SPCX Stake in Q3 Even as Wall Street Sees 38% Upside
SpaceX ($SPCX) stock has gained 15% over the past three months, supported by investor interest in the company’s expanding space and AI businesses. ...
Alphabet’s AI Drug Hunter Isomorphic Labs In Fundraising Talks to Hit $40B Valuation
Alphabet ($GOOGL) company Isomorphic Labs is reportedly set to raise new funds, which would value it at around $40 billion. According to a Bloomber...
Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?
On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab...
A Top Novartis (NVS) Shareholder Says 'The Party is Over' for its Dealmaking Team
On September 10, 2026, Reuters reported that Artisan Partners, among Novartis AG (NYSE:NVS)' 20 largest shareholders, publicly called for a shake-up of the Swiss drugmaker's board to improve oversight...
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions...
Failure of Novartis' Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker.
Novartis (NVS) Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial
Novartis AG (NYSE:NVS) has discontinued development of VHB937, also known as lifonebart, after the experimental ALS drug failed to meet both its primary and secondary endpoints in a Phase II trial involving...
Anthropic Builds San Francisco Biology Lab to Advance AI Drug Development
Anthropic built a real biology lab in the San Francisco Bay Area to test its artificial intelligence for making new medicines, according to an excl...
Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for...
Hedge Fund Resource Center